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Abstract Deceit and fraud in medical research is a serious problem for the cred-
ibility of published literature. Although estimating its prevalence is difficult,
reported incidences are alarming. The spectrum of the problem ranges from what
may seem as rather innocuous gift authorship to wholesale fabrication of data.
Potential factors which may have promoted fraud and deceit include financial gain,
personal fame, the competitive scientific environment and scientific hubris. Fraud
and deceit are difficult to detect and are generally brought to the fore by whistle-
blowers. Although most cases may be dealt with at an institutional level, regulatory
organisations such as the Committee on Publication Ethics (COPE) and Medical
Research Ethics Committee (MREC) have been established to monitor and try to
remedy the problem.
ª 2006 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.Introduction
Fraud and deceit in medical research corrupts the
scientific record and leads to false conclusions. It
leads to a loss in public trust in medical research
and doctors. Fraud in medical research affects all
grades of investigator.
Perhaps the most famous case in Britain was that
of Malcolm Pearce, a senior lecturer at St George’s
Hospital Medical School and Geoffrey Chamberlain,
Professor and head of the department.1 In 1994
they published a paper in the British Journal of Ob-
stetrics and Gynaecology, of which Pearce was
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claimed success in re-implanting an ectopic preg-
nancy. In the same issue, Pearce had published
a randomised controlled trial. A few months later,
a junior researcher in their department alerted au-
thorities that the re-implantation case was a work
of fiction and that the patients randomised in the
trial did not exist. The affair led to Chamberlain re-
signing and Pearce being struck off the medical reg-
ister. The story warranted front page attention in
the Daily Mail newspaper.
Although this was a rather sensational case,
fraud and deceit in medical research has a ‘path-
ogenesis’ and manifests itself in a number of ways.
In this paper the nature and causes of fraud and
deceit in medical research are examined as well as
potential solutions to the problem.blished by Elsevier Ltd. All rights reserved.
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The committee on Public Ethics (COPE) holds that
the principle underlying misconduct is intention to
cause others to regard as true that which is not
true.2 Misconduct, therefore, not only involves
a particular act or omission, but also the intention
of the researcher, author, editor, reviewer or pub-
lisher involved.
Although an honest mistake is very different
from deliberate fraud, it is not enough to say that
all human activity including research is prone to
error. The scientific record is equally at risk from
honest mistakes as from deliberate fraud. Hence it
is the responsibility of the authors to check their
work and ensure accuracy.
Prevalence of fraud and deceit
It is difficult to estimate the prevalence of fraud and
deceit in the medical literature directly, but an
indirect insight can be gained from questionnaire
surveys. One North American study reported that
36% of doctoral and post-doctoral students were
aware of an instance of scientific misconduct;
furthermore, 15% were willing to do whatever was
necessary to get a grant or publish a paper.3 Another
survey of Biostatistician members of International
Society for Clinical Biostatistics, who may be
thought of as unbiased and in a prime position to
observe fraud and deceit, revealed that 51% of re-
spondents knew of fraudulent projects. Different
forms of fraud such as fabrication and falsification
of data, deceptive reporting of results, suppression
of data, and deceptive design or analysis had been
observed in fairly similar numbers.4 This evidence
fairly convincingly debunks the idea that fraud or
deceit in medical research is a relatively minor
and isolated activity. It is indeed widespread.
Potentially dubious practices in
medical research
Plagiarism
Plagiarism can range from the unreferenced use of
others’ published or unpublished ideas to sub-
mission under ‘new’ authorship of a complete
paper, sometimes in a different language.2
Forging
Forging is the inventionof someor all of the research
data that are reported, including the description ofexperiments that were never performed.5 Cases of
forging have been well publicised in the past.6,7
Although forging is the most obvious form of fraud
and deceit in medical research, it is by no means
the only type of misconduct.
‘Cooking’ and ‘trimming’
Cooking refers to retaining and analysing only
those results that support the hypothesis being
investigated and ignoring data which may weaken
the results. Trimming involves smoothing the
irregularities in the data to make the results look
more convincing for publication. These offences
seem mild in comparison to plagiarism and forging
however they provide a first step for the vulnera-
ble researcher down the road of fraud and deceit.
Misuse of statistical techniques
Owing to the complexity of statistical analysis and
the difficulty many researchers have with it, fraud
and deceit can creep in unwittingly. With the
ready availability of menu driven statistical soft-
ware and lack of understanding of associated
hypotheses and assumptions, improper techniques
may be employed leading to misleading research.
Irresponsible authorship
Multi-authored papers have become increasingly
common over the past 10 years with some having
up to 40 authors. Often ‘authorship’ has been
granted for the need to accord recognition rather
than due to any direct scientific contribution to
the endeavour.
There is as yet no universally accepted defini-
tion of authorship. COPE guidelines state that the
award of authorship should balance intellectual
contributions to the conception, design, analysis
and writing against the collection of data and
other routine work. The guidelines go on to state
that if there is no task that can be reasonably
attributed to a particular individual then the
individual should not be credited with authorship.
Authorship carries important implications for
responsibility for thepublishedmaterial. All authors
carry the responsibility to check data and ensure its
honesty. Most journals now require authors to pro-
vide a signed statement that they have read the
manuscript prior to submission and are thus aware
of its contents. In cases where certain aspects of
a paper are beyond an individual’s capabilities, the
relevant section should be checked by someone
with the appropriate expertise who has not written
the particular contribution.
124 U. Jaffer, A.E.P. CameronRedundant publication
Redundant publication occurs when two or more
papers, without cross reference, share the same
hypothesis, data, discussion points or conclu-
sions.2 Although previous publication of an
abstract during the proceedings of meetings does
not preclude subsequent submission for publica-
tion, full disclosure should be made at the time
of submission. A somewhat similar practice,
known as ‘‘salami slicing’’ allows the production
of multiple papers by fragmentation of the same
data-set.
The consequences of fraud and deceit
Fraud and deceit in medical research may lead to
two major problems for science in general. Firstly,
there will be an erosion in trust in the overall
validity of scientific discoveries which may lead to
a slowing of the pace of research as investigators
spend more and more time trying to confirm the
work of others rather than building on it. And
secondly, fraud or deceit may lead to patient
management being instituted on evidence with
a less than firm base in scientific fact and hence
may not have the expected benefit and possibly
cause harm to patients.
A prominent case which highlights both of these
aspects is that of Mark Williams and Cameron
Bowie.8 Drs Bowie and Williams instituted a survey
of need of severely handicapped patients in the
community. The results were fascinating. Those
severely disabled people who were being seen
only by their GP and community nurse had far
more unmet needs than those who were also being
seen by a social worker or who were in contact
with a patient organisation. The results provided
empirical evidence of inadequate medicosocial as-
sessment, coincidentally reported at just the right
time to back the government’s community care
proposals. Later, Williams was investigated for
fraudulent behaviour (including lying about his
qualifications) and struck off the medical register
which resulted in all the research he was involved
in being withdrawn including this survey.
Dr Bowie lamented later at the time of
retraction that the paper had been ‘seminal’ in
community care reform and had done much good.
Unfortunately he personally had not looked at the
raw data and thus could not vouch for the honesty
of the paper and so had no alternative but to
withdraw it.
This case aptly demonstrates that any degree of
deceit and fraud may have a disastrous effect onmedical research in general owing to erosion of
confidence and mistrust in the scientific literature.
Potential causes of fraud and deceit
in medical research
There may be a variety of causes of fraud and
deceit in medical research. In generously funded,
industry supported research, clearly financial gain
may be an incentive. In centres of clinical re-
search, the motives may be more complex. Com-
petition, discussed below, or simply the desire for
fame may be contributing factors.
Angell argues that the highly pressurised envi-
ronment in which medical research is carried out
has given rise to fraud and deceit.9 He points out
that because promotion and funding of physicians
in academic medicine are closely linked to the
number of their publications, investigators feel im-
pelled to publish as frequently as possible. This
pressure leads to, for instance, trivial studies
being undertaken because they yield rapid results,
needlessly reporting the same study in instal-
ments, reporting a study more than once, and list-
ing as authors people only marginally involved in
the study or even to outright forging.
Hubris, where a researcher just ‘knows’ what
the result of a study ought to be and manipulates
or fabricates the data to confirm this belief, may
lead to fraud. The most celebrated case is that of
William McBride who gained worldwide acclaim for
discovering that thalidomide caused birth defects
but his subsequent studies showing the same for
the drug debendox were falsified. He subsequently
admitted forging the data ‘‘in the interests of
humanity’’.
Angell further proposes that an effective way to
reduce these offences and affirm the supremacy of
substance over volume in scientific research would
be to place a ceiling on the number of publications
that can be considered in evaluating a candidate
for promotion or funding. Each publication would
then receive commensurately more attention,
both from the researcher and from those judging
the work.
In the US setting, Petesdorf describes a ‘‘pre-
med syndrome’’ in the pathogenesis of fraud and
deception.10 He argues that the extraordinary size
of science (which makes supervision of young in-
vestigators difficult), and competition, both pro-
fessional and economic, has lead to fertile soil
for fraud. Petersdoft suggests that solutions
include more careful selection of personnel, re-
duction of excessively large research groups, and
closer examination of work at all levelsdthe
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stitution. He also suggests that institutions should
have in place mechanisms to investigate research
fraud when it is uncovered.
Statistical methods for the detection
of data fabrication
Various statistical methods are available to in-
vestigate whether data is likely to be fabricated or
not.11 The techniques detect ‘strange’ patterns in
the data including studying outliers, inliers, over-
dispersion, underdispersion and correlations or
lack thereof. These techniques all rest upon the
premise that it is quite difficult to invent plausible
data, particularly highly dimensional multivariate
data. The multicentric nature of clinical trials
also offers an opportunity to check the plausibility
of the data submitted by one centre by comparing
them with the data from all other centres.
For instance in a randomised blinded trial
comparing two groups, means and variances be-
tween baseline values can be compared between
the two groups. Values which differ greatly would
suggest that the two groups could not have been
formed by random allocation. Digit preference has
been described as a test, although is not itself
evidence of misconduct. It is conceivable that if
two individuals were given the task to record data
for the treatment group and another the data from
the control group that digit preference may occur.
This could not happen if blinding had taken place.
Although statistical methods have been de-
scribed, few examples of their application have
been published. Also, statistical methods alone are
not proof of data fabrication. Statistical methods
can however be used in the setting of randomised
trials where raw data is available.
Whistleblowing
Most fraud is probably detected by the suspicions
of a colleague in the relevant department. In the
context of witnessing fraudulent behaviour by
a colleague, one should first try to assess whether
this is likely to be deliberate or accidental. In the
latter case, all that would be necessary would be
to inform the colleague involved.
In the case of clearly deliberately fraudulent
work, a letter could be sent to the editor of the
journal in which the paper appeared which could
later be published as an erratum, ideally with the
consent of the offending author as a public admis-
sion of culpability. If it becomes clear that this isa pattern of behaviour and clearly negligent in
nature, one would most likely wish to discuss the
matter with an experienced colleague whom one
trusts. If it seems that the matter should be
pursued, the next step would be to initiate the
institution’s formal procedures or consult COPE for
advice as to how to proceed. This is a particularly
thorny issue for junior members of a team and
could have serious personal consequences.
The 1998 Public Interest Disclosure Act gives
whistleblowers the right to claim against wrongful
dismissal, provided the correct procedures have
been followed, but otherwise does not protect
employment. A system where employment is
protected under these circumstances would be
difficult to implement owing to the intimacy of
working relations in a research institution.
Guidelines and watchdogs
Kassirer12 argues that lack of effective accountabil-
ity and regulatory programs will result in draconian
measures being instituted by governmental organi-
sations which will limit our ability to perform re-
search. He advocates adequate and stringent self
regulation to rectify matters before responsibility
is taken out of the hands of scientists.
The US moved in the 1980s to establish accept-
ability limits to medical research,13 however it was
thought that the prevalence of fraud and deceit in
Britain was low enough not to require explicit guid-
ance. Subsequent headline stories and other initia-
tives which produced the Uniform Requirements for
Manuscripts Submitted to Biomedical Journals,
commonly known as the Vancouver guidelines14
led to the more recent establishment of COPE,
founded in 1997 by editors of British biomedical
journals, including those of the BMJ, Gut and the
Lancet.2
COPE has five stated aims: (1) to advise on cases
brought by editors; (2) to hold meetings and
publish an annual report in which its members or
invited speakers discuss current issues of publica-
tion ethics and describe cases brought to its
attention; (3) to produce guidance on good prac-
tice; (4) to encourage research; (5) to offer
teaching and training. It does not have a legal
standing but aims to cause change by shaming the
British establishment into mounting a proper
response to inappropriate behaviour. Whether
this will be successful is dubious; from the US
experience Rennie15 comments that a legal rather
than scientific method is necessary to deal with
fraud as scientists are not trained in conflict reso-
lution. In an editorial in the British Medical Journal
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Bowie case amongst others) Smith16 stated that
‘‘our experience with COPE makes it clear that
once editors begin to pay serious attention to
misconduct it is there before their eyes’’, and
called for a national body to oversee all scientific
research. The same issue of the journal devoted
several articles to the subject of research fraud,
indicating the seriousness of the problem.
Research governance
Efforts to provide a national framework to monitor
and regulate standards of behaviour by medical
researchers has led to the establishment of
Research Governance for NHS and joint projects
with partners (http://www.doh.gov.uk/research/
whatsnew.htm;). The governance framework was
published by the Department of Health. This pro-
vides a register of research activity in each institu-
tion, sets out standards, delivery mechanisms, and
monitoring arrangements. Research governance
links in with mandatory submission to the Medical
Research Ethics Committees.17
Conclusions
Fraud and deceit in medical research is of signif-
icant prevalence and potentially widespread. Its
scale can range from what may seem like a rela-
tively innocuous gift authorship for a head of
department or senior colleague to wholesale fab-
rication of data. Through Research Governance,
investigators must maintain vigilance to the dan-
gers of deceit and fraud and should take reparative
steps when necessary. Proof of serious misconduct
is often difficult to establish without ‘eye-witness’
evidence as statistical tests cannot provide de-
finitive proof in themselves. The research commu-
nity should discourage the environment where
publication at any cost is acceptable. Perhaps
the principles of ethical behaviour should be
introduced into the curricula of doctors and
medical scientists.
Fraud, whether intentional or accidental, is
deceitful and concealed so it will be difficult topredict whether the new guidelines and regulatory
bodies will be effective; as in so many other area
of life, the trust extended to authors will always
be open to abuse.
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